Understanding the Belgian healthcare budget and its impact on pharmaceutical market access
Healthcare budgets are more than financial figures. They determine how much funding is available to provide healthcare services, reimburse medicines and introduce medical innovations. In Belgium, where healthcare expenditure continues to grow, maintaining a balance between patient access to innovative treatments and the financial sustainability of the healthcare system is a constant challenge.
For pharmaceutical companies seeking reimbursement in Belgium, understanding how the healthcare budget is established, allocated and monitored is essential. After all, successful market access is not determined by clinical value and pricing alone. The availability of public funding and the broader budgetary framework also play a critical role.
But how exactly does Belgium determine its healthcare budget? Who is responsible for approving it? And how does the pharmaceutical industry fit into this financial framework?
1. What exactly is a budget?
A budget represents the financial resources expected to be available or required over a defined period, usually one financial year.
Every organisation, including public authorities, needs to estimate its financial requirements in advance. However, budgeting does not stop once the financial year begins. Throughout the year, expenditure is regularly monitored and compared with the approved budget.
These interim assessments help identify potential financial shortfalls and determine whether corrective measures are necessary. Such measures may include reallocating resources, limiting expenditure or introducing additional financial contributions.
At government level, the sum of the different public expenditure budgets forms the overall government budget.
In Belgium, healthcare financing is largely organised at federal level through the compulsory health insurance system, although the communities also have specific healthcare responsibilities and corresponding budgets, including areas such as prevention and elderly care.
2. Who determines the Belgian healthcare budget?
The federal healthcare budget is established through a structured consultation and approval process involving several stakeholders. The Minister of Social Affairs and Public Health represents the government in the preparation of the healthcare budget. Within this framework, the National Institute for Health and Disability Insurance (NIHDI) plays a central coordinating role.
The process involves several important bodies:
- The Insurance Committee: plays a key role in the preparation and discussion of the healthcare budget and submits a budget proposal.
- The General Council: brings together representatives of health insurance funds, employers, employees, self-employed individuals and the government. It is responsible for the overall governance of the compulsory health insurance system and its financial framework.
- The Federal Government: takes the final decisions and formally approves the budget.
Once approved, the relevant budgetary decisions are published in the Belgian Official Gazette (Belgisch Staatsblad).
This process ensures that the healthcare budget reflects input from different stakeholders while remaining aligned with the government’s broader financial and healthcare policy objectives.
3. How is the healthcare budget calculated?
Determining the healthcare budget is not simply a matter of increasing last year’s expenditure by a fixed percentage. The starting point is generally the historical expenditure, which provides insight into existing healthcare consumption and financial commitments. However, several additional parameters influence the estimated budget requirements:
- Demographic developments: an ageing population and population growth can increase demand for healthcare services.
- Epidemiological trends: changes in disease prevalence and incidence influence healthcare needs.
- Healthcare consumption: changes in the use of healthcare services and treatments affect overall expenditure.
- Inflation: increasing prices and operating costs influence the financial resources required.
- Policy measures: new government initiatives and changes to reimbursement policies can affect expenditure.
- Medical innovation: new medicines, technologies and treatment approaches can introduce additional costs but may also generate significant health benefits.
Medical innovation deserves particular attention. Introducing innovative treatments can increase short-term healthcare expenditure, especially when new therapies address previously unmet medical needs or offer treatment options for complex diseases.
Nevertheless, innovation can also improve patient outcomes, reduce complications and potentially avoid other healthcare costs.
The Belgian government therefore needs to consider both the financial impact and the potential added value of medical innovation when estimating future healthcare expenditure.
4. The evolution of Belgium’s healthcare budget
Belgium’s healthcare expenditure has increased substantially in recent years, reflecting demographic developments, growing healthcare needs and the introduction of innovative treatments. Belgium’s nominal GDP is projected to increase from approximately €602 billion in 2023 to €663 billion in 2026. Public healthcare expenditure represents approximately 7% of GDP. The total gross healthcare budget managed by NIHDI illustrates this continued growth:
- 2023: €40.4 billion
- 2026: €46.8 billion
The budget is divided into five expenditure categories, with healthcare benefits representing the largest component. The gross budget allocated to healthcare benefits increased from €35.3 billion in 2023 to €41.3 billion in 2026, representing growth of approximately 17%.
However, the gross budget does not necessarily correspond to the amount ultimately available for healthcare expenditure. To determine the net budget available for healthcare benefits, expected refunds under Managed Entry Agreements (MEAs), together with predefined non-spendable budgetary amounts, are deducted.
This distinction between gross and net expenditure is particularly important when assessing the actual financial resources available to fund healthcare and innovative medicines.
5. The pharmaceutical budget: A growing but closely monitored expenditure
Medicines represent a substantial component of Belgian healthcare expenditure.
The net medicines budget has evolved as follows:
| Year | Net medicines budget |
|---|---|
| 2023 | €5.6 billion |
| 2024 | €5.8 billion |
| 2025 | €6.5 billion |
| 2026 | €6.8 billion |
The figures demonstrate the increasing financial resources allocated to reimbursed medicines. However, this growth takes place within a strict budgetary framework. Belgium aims to ensure sustainable pharmaceutical expenditure through dedicated budgetary targets and financial safeguard mechanisms. The Multiannual Pharmaceutical Framework 2026–2029 introduces a more predictable growth trajectory, with the net medicines budget capped at 17.3% of net authorised healthcare expenditure. This framework aims to provide greater financial predictability while maintaining the capacity to reimburse innovative treatments.
An important consideration is that more than half of pharmaceutical expenditure is attributable to medicines used in hospitals. This includes significant expenditure on oncology treatments, biologics, immunotherapies, diabetes treatments and orphan medicines.
Consequently, hospital medicines play an increasingly important role in the overall pharmaceutical budget and its financial monitoring.
6. Managed Entry Agreements: Balancing innovation and affordability
One of the mechanisms Belgium uses to manage uncertainty surrounding innovative medicines is the Managed Entry Agreement (MEA). These agreements, established under Articles 111, 112 and 113, involve financial arrangements between the government and pharmaceutical companies. They are particularly relevant when uncertainties remain regarding the clinical, economic or budgetary impact of a new medicine.
For example, uncertainty may relate to:
- The number of patients eligible for treatment.
- The expected treatment duration.
- The real-world clinical effectiveness.
- The anticipated budget impact.
- The long-term financial consequences of reimbursement.
MEAs allow reimbursement to take place while introducing arrangements to manage these uncertainties. From a budgetary perspective, expected refunds under these agreements are incorporated into the calculation of the net healthcare benefits budget. For pharmaceutical companies, this means that the reimbursement strategy must go beyond the initial pricing proposal. The potential financial implications of an MEA should also be considered when preparing a Belgian market access strategy.
7. What happens when pharmaceutical expenditure exceeds the budget?
Budgetary planning is one thing. Controlling actual expenditure is another. Throughout the financial year, actual healthcare and pharmaceutical expenditure is monitored and compared with the approved budgetary targets. Pharma.be contributes to the monitoring and forecasting of pharmaceutical expenditure in Belgium. Through engagement with its member companies, it supports the refinement of expenditure estimates and projections for the current and upcoming budgetary years.
When pharmaceutical expenditure exceeds the predefined budget, corrective measures may be activated to restore financial balance. Belgium has several mechanisms available to manage pharmaceutical expenditure and ensure that the financial responsibility is shared appropriately. These mechanisms can include financial contributions from pharmaceutical companies, expenditure containment measures and adjustments to reimbursement arrangements. The underlying principle is straightforward: access to innovative medicines must remain compatible with the financial sustainability of the compulsory health insurance system. For pharmaceutical companies, understanding these mechanisms is therefore not merely an administrative exercise. They can have a direct impact on the net financial return of a reimbursed medicine.
8. What does this mean for pharmaceutical companies and market access?
The Belgian healthcare budget has a direct influence on the environment in which pharmaceutical companies introduce and commercialise innovative medicines. A positive clinical assessment and an attractive price proposal are important, but they do not automatically guarantee reimbursement. The budgetary impact of a new medicine is an increasingly important consideration throughout the market access process.
Companies should therefore anticipate several key questions:
- How many patients are expected to align with the (proposed) reimbursement criteria?
- What is the expected annual budget impact (versus drug budget (level 2) and versus overall healthcare expenditures (level 3))?
- How will the introduction of the medicine affect existing treatment patterns?
- Could the medicine replace or reduce expenditure on existing treatments?
- Is a Managed Entry Agreement a strategic fallback option (lower net price versus offcial list price)?
- What financial contributions or expenditure-containment mechanisms could apply?
- How will the medicine’s budget impact evolve following reimbursement and potential indication extensions?
A robust Budget Impact Analysis (BIA) is consequently an essential component of the Belgian reimbursement dossier. It should not only estimate the expected expenditure associated with a new treatment but also provide realistic scenarios that allow decision-makers to understand the potential financial consequences under different assumptions.
In an environment where pharmaceutical expenditure is closely monitored, a transparent, evidence-based and strategically developed budget impact analysis can strengthen the reimbursement strategy.
Conclusion: Understanding the budget is understanding market access
Belgium faces a continuous challenge: ensuring timely access to innovative medicines while safeguarding the financial sustainability of its healthcare system.
The healthcare budget is therefore much more than an annual financial exercise. It is a strategic instrument that determines the resources available to patients, healthcare providers and pharmaceutical innovation.
For pharmaceutical companies, understanding the Belgian budgetary process, the allocation of healthcare expenditure, the pharmaceutical budget framework and the mechanisms used to control spending is essential when developing a successful market access strategy.
At Hebias, we believe that successful market access starts with understanding the healthcare system in which a medicine needs to find its place.
By combining expertise in Belgian reimbursement procedures, pharmaceutical expenditure, budget impact modelling and Managed Entry Agreements, Hebias supports pharmaceutical companies in navigating the financial and procedural complexities of market access in Belgium.
Because getting a medicine reimbursed is not just about demonstrating its value. It is also about making that value financially understandable and sustainable for the healthcare system.
Sources:
National Institute for Health and Disability Insurance (NIHDI). Les organes du Service des soins de santé. [cited 2026 31 August]; Available from: https://www.inami.fgov.be/fr/l-inami/nos-organes/les-organes-du-service-des-soins-de-sante.
National Institute for Health and Disability Insurance (NIHDI), Gezondheidszorgbegroting 2026 (Nota ARGV 2025/069), Algemene Raad (ARGV), Editor. 2025.
National Institute for Health and Disability Insurance (NIHDI). De terugbetaling van een geneesmiddel. 2026 28/10/2026]; Available from: https://www.riziv.fgov.be/nl/thema-s/verzorging-kosten-en-terugbetaling/wat-het-ziekenfonds-terugbetaalt/geneesmiddelen/geneesmiddel-terugbetalen
National Institute for Health and Disability Insurance (NIHDI). De organen van de Dienst voor geneeskundige verzorging. 2026 29/08/2026]; Available from: https://www.riziv.fgov.be/nl/riziv/onze-organen/de-organen-van-de-dienst-voor-geneeskundige-verzorging.
National Institute for Health and Disability Insurance (NIHDI). Commissie Tegemoetkoming Geneesmiddelen. 2026; Available from: https://www.riziv.fgov.be/nl/riziv/onze-organen/commissie-tegemoetkoming-geneesmiddelen.
National Institute for Health and Disability Insurance (NIHDI). Commissie voor advies in geval van tijdelijke tegemoetkoming voor het gebruik van een geneesmiddel. 2026 29/08/2026]; Available from: https://www.riziv.fgov.be/nl/riziv/onze-organen/de-organen-van-de-dienst-voor-geneeskundige-verzorging/commissie-voor-advies-in-geval-van-tijdelijke-tegemoetkoming-voor-het-gebruik-van-een-geneesmiddel
Rijksinstituut voor Ziekte- en Invaliditeitsverzekering (RIZIV) (NIHDI), Gezondheidszorgbegroting 2023, Voorstel van de regeringsdelegatie aan de Algemene Raad van het RIZIV, Editor. 2022.
Rijksinstituut voor Ziekte- en Invaliditeitsverzekering (RIZIV) (NIHDI), Gezondheidszorgbegroting 2024, Voorstel van de regeringsdelegatie aan de Algemene Raad van het RIZIV Editor. 2023.
Rijksinstituut voor Ziekte- en Invaliditeitsverzekering (RIZIV) (NIHDI), Gezondheidszorgbegroting 2025, Beslissing van de ministerraad, Editor. 2024.
Belgische Kamer van Volksvertegenwoordigers, Openbare commissievergadering onderwerp (07.02), Commissie voor Gezondheidszorg en Gelijke Kansen, Editor. 2025.
Federaal Planbureau. Regionale economische vooruitzichten 2026-2031, juli 2026 – Statistische bijlage. 2026; Available from: https://www.plan.be/nl/data/regionale-economische-vooruitzichten-2026-2031
Navigating the Belgian pharmaceutical pricing & reimbursement landscape
Discover the Belgian market by downloading our free market overview document.
New in Belgian market access? – Hebias
🪄